You are here

2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk.

Title2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk.
Publication TypeJournal Article
Year of Publication2018
AuthorsColantonio, LD, Booth, JN, Bress, AP, Whelton, PK, Shimbo, D, Levitan, EB, Howard, G, Safford, MM, Muntner, P
JournalJ Am Coll Cardiol
Volume72
Issue11
Pagination1187-1197
Date Published2018 Sep 11
ISSN1558-3597
Abstract

BACKGROUND: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) blood pressure (BP) guideline provides updated recommendations for antihypertensive medication initiation and intensification.OBJECTIVES: Determine the risk for cardiovascular disease (CVD) events among adults recommended and not recommended antihypertensive medication initiation or intensification by the 2017 ACC/AHA BP guideline.METHODS: The authors analyzed data for black and white REGARDS (REasons for Geographic And Racial Differences in Stroke) study participants (age ≥45 years). Systolic BP (SBP) and diastolic BP (DBP) were measured twice at baseline (2003 to 2007) and averaged. Participants not taking (n = 14,039) and taking (n = 15,179) antihypertensive medication were categorized according to their recommendations for antihypertensive medication initiation and intensification by the 2017 ACC/AHA guideline. Overall, 4,094 CVD events (stroke, coronary heart disease, and heart failure) occurred by December 31, 2014.RESULTS: Among participants not taking antihypertensive medication, 34.4% were recommended pharmacological antihypertensive treatment initiation. The CVD event rate per 1,000 person-years among participants recommended antihypertensive medication initiation with SBP/DBP ≥140/90 mm Hg was 22.7 (95% confidence interval [CI]: 20.3 to 25.0). Among participants with SBP/DBP 130 to 139/80 to 89 mm Hg, the CVD event rate was 20.5 (95% CI: 18.5 to 22.6) and 3.4 (95% CI: 2.4 to 4.4) for those recommended and not recommended antihypertensive medication initiation, respectively. Among participants taking antihypertensive medication, 62.8% were recommended treatment intensification. The CVD event rate per 1,000 person-years among participants recommended treatment intensification was 33.6 (95% CI: 31.5 to 35.6) and 22.4 (95% CI: 20.8 to 23.9) for those with SBP/DBP ≥140/90 mm Hg and 130 to 139/80 to 89 mm Hg, respectively.CONCLUSIONS: Implementing the 2017 ACC/AHA guideline would direct antihypertensive medication initiation and intensification to adults with high CVD risk.

DOI10.1016/j.jacc.2018.05.074
Alternate JournalJ. Am. Coll. Cardiol.
PubMed ID30189994
Grant ListK01 HL133468 / HL / NHLBI NIH HHS / United States
K24 HL111154 / HL / NHLBI NIH HHS / United States
U01 NS041588 / NS / NINDS NIH HHS / United States
R01 HL080477 / HL / NHLBI NIH HHS / United States
K24 HL125704 / HL / NHLBI NIH HHS / United States